NCT01702181View on ClinicalTrials.gov

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Atopic Dermatitis
Interventions
DRUG

OPA-15406

0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days

DRUG

Tacrolimus

0.1% concentration of tacrolimus.

DRUG

Placebo

Trial Locations (12)

27262

High Point

32073

Orange Park

33609

Tampa

36608

Mobile

46032

Carmel

71913

Hot Springs

75230

Dallas

77845

College Station

78229

San Antonio

92697

Irvine

97210

Portland

08009

Berlin

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01702181 - A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis | Biotech Hunter | Biotech Hunter